Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer

B. Detti, P. Bonomo, L. Masi, R. Doro, S. Cipressi, C. Iermano, I. Bonucci, D. Franceschini, L. Di Brina, M. Bakhi, G. Simontacchi, I. Meattini, L. Livi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To report a clinical experience in stereotactic body radiation therapy (SBRT) for isolated nodal metastases from prostate cancer. Materials and methods: Between November 2011 and December 2013, 30 patients (39 lesions) were treated with SBRT, delivered using Cyberknife, for recurrent prostate cancer with isolated nodal metastases. Prescribed doses and schedules of fractionation varied, ranging from 24 Gy in 1 fraction to 36 Gy in 3 fractions. Most commonly used schedules were 30 Gy in 3 fractions and 36 in Gy in 3 fractions on alternating days. Biochemical response, acute and late toxicity were analyzed. Results: At a median follow-up of 12 months (range 2–24.9), a significant reduction of PSA was observed in 24 cases, while PSA was stable in 1 case and raised in 9 cases. At the time of analysis, among the 30 patients treated, two were dead for systemic disease; 12 patients experienced a relapse of disease in other sites. Sixteen patients were still free of disease. In 24 cases, imaging evaluation 3 months after treatment was available. No in-field recurrence was detected. SBRT was well tolerated: One patient experienced G2 acute genitourinary toxicity. Late toxicity was evaluated in patients with more than 6 months of follow-up, and only one complained G1 proctitis. We did not observe any acute or late severe toxicity (≥G3). Conclusions: Our experience shows that SBRT for isolated nodal relapse from prostate cancer is a safe treatment, with promising results in terms of efficacy.

Original languageEnglish
Pages (from-to)1197-1203
Number of pages7
JournalWorld Journal of Urology
Volume33
Issue number8
DOIs
Publication statusPublished - Aug 27 2015

Fingerprint

Prostatic Neoplasms
Radiotherapy
Recurrence
Appointments and Schedules
Dose Fractionation
Neoplasm Metastasis
Proctitis
Therapeutics

Keywords

  • Cyberknife
  • Nodal relapse
  • Prostate cancer
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Urology

Cite this

Detti, B., Bonomo, P., Masi, L., Doro, R., Cipressi, S., Iermano, C., ... Livi, L. (2015). Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. World Journal of Urology, 33(8), 1197-1203. https://doi.org/10.1007/s00345-014-1427-x

Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. / Detti, B.; Bonomo, P.; Masi, L.; Doro, R.; Cipressi, S.; Iermano, C.; Bonucci, I.; Franceschini, D.; Di Brina, L.; Bakhi, M.; Simontacchi, G.; Meattini, I.; Livi, L.

In: World Journal of Urology, Vol. 33, No. 8, 27.08.2015, p. 1197-1203.

Research output: Contribution to journalArticle

Detti, B, Bonomo, P, Masi, L, Doro, R, Cipressi, S, Iermano, C, Bonucci, I, Franceschini, D, Di Brina, L, Bakhi, M, Simontacchi, G, Meattini, I & Livi, L 2015, 'Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer', World Journal of Urology, vol. 33, no. 8, pp. 1197-1203. https://doi.org/10.1007/s00345-014-1427-x
Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C et al. Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. World Journal of Urology. 2015 Aug 27;33(8):1197-1203. https://doi.org/10.1007/s00345-014-1427-x
Detti, B. ; Bonomo, P. ; Masi, L. ; Doro, R. ; Cipressi, S. ; Iermano, C. ; Bonucci, I. ; Franceschini, D. ; Di Brina, L. ; Bakhi, M. ; Simontacchi, G. ; Meattini, I. ; Livi, L. / Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. In: World Journal of Urology. 2015 ; Vol. 33, No. 8. pp. 1197-1203.
@article{d2c8ddb6682141018a41b07233e1de7a,
title = "Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer",
abstract = "Purpose: To report a clinical experience in stereotactic body radiation therapy (SBRT) for isolated nodal metastases from prostate cancer. Materials and methods: Between November 2011 and December 2013, 30 patients (39 lesions) were treated with SBRT, delivered using Cyberknife, for recurrent prostate cancer with isolated nodal metastases. Prescribed doses and schedules of fractionation varied, ranging from 24 Gy in 1 fraction to 36 Gy in 3 fractions. Most commonly used schedules were 30 Gy in 3 fractions and 36 in Gy in 3 fractions on alternating days. Biochemical response, acute and late toxicity were analyzed. Results: At a median follow-up of 12 months (range 2–24.9), a significant reduction of PSA was observed in 24 cases, while PSA was stable in 1 case and raised in 9 cases. At the time of analysis, among the 30 patients treated, two were dead for systemic disease; 12 patients experienced a relapse of disease in other sites. Sixteen patients were still free of disease. In 24 cases, imaging evaluation 3 months after treatment was available. No in-field recurrence was detected. SBRT was well tolerated: One patient experienced G2 acute genitourinary toxicity. Late toxicity was evaluated in patients with more than 6 months of follow-up, and only one complained G1 proctitis. We did not observe any acute or late severe toxicity (≥G3). Conclusions: Our experience shows that SBRT for isolated nodal relapse from prostate cancer is a safe treatment, with promising results in terms of efficacy.",
keywords = "Cyberknife, Nodal relapse, Prostate cancer, Stereotactic radiotherapy",
author = "B. Detti and P. Bonomo and L. Masi and R. Doro and S. Cipressi and C. Iermano and I. Bonucci and D. Franceschini and {Di Brina}, L. and M. Bakhi and G. Simontacchi and I. Meattini and L. Livi",
year = "2015",
month = "8",
day = "27",
doi = "10.1007/s00345-014-1427-x",
language = "English",
volume = "33",
pages = "1197--1203",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer

AU - Detti, B.

AU - Bonomo, P.

AU - Masi, L.

AU - Doro, R.

AU - Cipressi, S.

AU - Iermano, C.

AU - Bonucci, I.

AU - Franceschini, D.

AU - Di Brina, L.

AU - Bakhi, M.

AU - Simontacchi, G.

AU - Meattini, I.

AU - Livi, L.

PY - 2015/8/27

Y1 - 2015/8/27

N2 - Purpose: To report a clinical experience in stereotactic body radiation therapy (SBRT) for isolated nodal metastases from prostate cancer. Materials and methods: Between November 2011 and December 2013, 30 patients (39 lesions) were treated with SBRT, delivered using Cyberknife, for recurrent prostate cancer with isolated nodal metastases. Prescribed doses and schedules of fractionation varied, ranging from 24 Gy in 1 fraction to 36 Gy in 3 fractions. Most commonly used schedules were 30 Gy in 3 fractions and 36 in Gy in 3 fractions on alternating days. Biochemical response, acute and late toxicity were analyzed. Results: At a median follow-up of 12 months (range 2–24.9), a significant reduction of PSA was observed in 24 cases, while PSA was stable in 1 case and raised in 9 cases. At the time of analysis, among the 30 patients treated, two were dead for systemic disease; 12 patients experienced a relapse of disease in other sites. Sixteen patients were still free of disease. In 24 cases, imaging evaluation 3 months after treatment was available. No in-field recurrence was detected. SBRT was well tolerated: One patient experienced G2 acute genitourinary toxicity. Late toxicity was evaluated in patients with more than 6 months of follow-up, and only one complained G1 proctitis. We did not observe any acute or late severe toxicity (≥G3). Conclusions: Our experience shows that SBRT for isolated nodal relapse from prostate cancer is a safe treatment, with promising results in terms of efficacy.

AB - Purpose: To report a clinical experience in stereotactic body radiation therapy (SBRT) for isolated nodal metastases from prostate cancer. Materials and methods: Between November 2011 and December 2013, 30 patients (39 lesions) were treated with SBRT, delivered using Cyberknife, for recurrent prostate cancer with isolated nodal metastases. Prescribed doses and schedules of fractionation varied, ranging from 24 Gy in 1 fraction to 36 Gy in 3 fractions. Most commonly used schedules were 30 Gy in 3 fractions and 36 in Gy in 3 fractions on alternating days. Biochemical response, acute and late toxicity were analyzed. Results: At a median follow-up of 12 months (range 2–24.9), a significant reduction of PSA was observed in 24 cases, while PSA was stable in 1 case and raised in 9 cases. At the time of analysis, among the 30 patients treated, two were dead for systemic disease; 12 patients experienced a relapse of disease in other sites. Sixteen patients were still free of disease. In 24 cases, imaging evaluation 3 months after treatment was available. No in-field recurrence was detected. SBRT was well tolerated: One patient experienced G2 acute genitourinary toxicity. Late toxicity was evaluated in patients with more than 6 months of follow-up, and only one complained G1 proctitis. We did not observe any acute or late severe toxicity (≥G3). Conclusions: Our experience shows that SBRT for isolated nodal relapse from prostate cancer is a safe treatment, with promising results in terms of efficacy.

KW - Cyberknife

KW - Nodal relapse

KW - Prostate cancer

KW - Stereotactic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84938998914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938998914&partnerID=8YFLogxK

U2 - 10.1007/s00345-014-1427-x

DO - 10.1007/s00345-014-1427-x

M3 - Article

VL - 33

SP - 1197

EP - 1203

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 8

ER -